Inovio Pharmaceuticals
113 hedge funds and large institutions have $26.2M invested in Inovio Pharmaceuticals in 2023 Q4 according to their latest regulatory filings, with 15 funds opening new positions, 23 increasing their positions, 32 reducing their positions, and 25 closing their positions.
979% more call options, than puts
Call options by funds: $313K | Put options by funds: $29K
21% more capital invested
Capital invested by funds: $21.6M → $26.2M (+$4.53M)
0.18% less ownership
Funds ownership: 1.73% → 1.55% (-0.18%)
9% less funds holding
Funds holding: 124 → 113 (-11)
28% less repeat investments, than reductions
Existing positions increased: 23 | Existing positions reduced: 32
40% less first-time investments, than exits
New positions opened: 15 | Existing positions closed: 25
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GCP
GSA Capital Partners
London,
United Kingdom
|
+$1.44M |
| 2 |
Renaissance Technologies
New York
|
+$990K |
| 3 |
Morgan Stanley
New York
|
+$320K |
| 4 |
Acadian Asset Management
Boston,
Massachusetts
|
+$176K |
| 5 |
Jane Street
New York
|
+$79.5K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$1.71M |
| 2 |
D.E. Shaw & Co
New York
|
-$1.16M |
| 3 |
BlackRock
New York
|
-$817K |
| 4 |
GC
GMT Capital
Atlanta,
Georgia
|
-$589K |
| 5 |
Two Sigma Investments
New York
|
-$206K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
MIC
126
Means Investment Company
Bangor,
Maine
| – | -$3.9K | -834 | Closed |
|
|
AWM
127
Apollon Wealth Management
Mount Pleasant,
South Carolina
| – | -$3.89K | -833 | Closed |
|
128
Credit Agricole
Montrouge Cedex,
France
| – | -$3.11K | -667 | Closed |
|
|
CUAMC
129
China Universal Asset Management Company
Shanghai,
China
| – | -$2.68K | -574 | Closed |
|
130
EARNEST Partners
Atlanta,
Georgia
| – | -$1.07K | -229 | Closed |
|
|
PA
131
Parallel Advisors
San Francisco,
California
| – | -$498 | -107 | Closed |
|
|
CSPIA
132
Cary Street Partners Investment Advisory
Richmond,
Virginia
| – | -$195 | -42 | Closed |
|
|
SS
133
Sunbelt Securities
Houston,
Texas
| – | -$97 | -21 | Closed |
|
|
HI
134
Harbour Investments
Madison,
Wisconsin
| – | -$75 | -16 | Closed |
|
|
HNB
135
Huntington National Bank
Columbus,
Ohio
| – | -$39 | -8 | Closed |
|
|
AFG
136
Albion Financial Group
Salt Lake City,
Utah
| – | -$25 | -5 | Closed |
|
|
SPIA
137
Steward Partners Investment Advisory
New York
| – | -$22 | -5 | Closed |
|
INO Hedge Fund Activity: Q4 2023 in Review
113 of the 6,859 institutional investors tracked by Wall St. Rank reported a position in Inovio Pharmaceuticals (INO) for Q4 2023, worth a combined $26.2M — up 21% from $21.6M a quarter earlier.
Sellers outnumbered buyers: 25 funds closed out of INO and 15 opened new positions — a net loss of 10 holders — while 32 trimmed existing stakes and 23 added.
The largest buyer was GSA Capital Partners, adding an estimated $1.44M. The largest seller was Millennium Management, cutting an estimated $1.71M.
- 113 institutional investors held Inovio Pharmaceuticals (INO) as of Q4 2023, down from 124 in Q3 2023.
- Funds reported $26.2M of Inovio Pharmaceuticals stock for Q4 2023, up 21% quarter-over-quarter.
- 15 funds opened new Inovio Pharmaceuticals positions in Q4 2023 and 25 closed out, a net change of -10 holders.
- The largest Inovio Pharmaceuticals buyer in Q4 2023 was GSA Capital Partners, an estimated $1.44M added.
- The largest Inovio Pharmaceuticals seller in Q4 2023 was Millennium Management, an estimated $1.71M sold.
Based on aggregated 13F filings for Q4 2023.